[1]周 春,周卫忠,刘 圣,等.无水乙醇明胶海绵混合物栓塞治疗肝癌合并中重度肝动脉门静脉分流的疗效分析[J].介入放射学杂志,2017,(09):793-798.
 ZHOU Chun,ZHOU Weizhong,LIU Sheng,et al.Chemoembolization by using ethanol- soaked gelatin sponge combined with chemotherapeutic drugs and/or iodized oil for HCC complicated by moderate- to- severe hepatic arterio- portal shunts: analysis of curative effect[J].journal interventional radiology,2017,(09):793-798.
点击复制

无水乙醇明胶海绵混合物栓塞治疗肝癌合并中重度肝动脉门静脉分流的疗效分析()

PDF下载中关闭

分享到:

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
期数:
2017年09期
页码:
793-798
栏目:
肿瘤介入
出版日期:
2017-09-25

文章信息/Info

Title:
Chemoembolization by using ethanol- soaked gelatin sponge combined with chemotherapeutic drugs and/or iodized oil for HCC complicated by moderate- to- severe hepatic arterio- portal shunts: analysis of curative effect
作者:
周 春 周卫忠 刘 圣 周春高 王 斌 王绍显 施海彬
Author(s):
ZHOU Chun ZHOU Weizhong LIU Sheng ZHOU Chungao WANG Bin WANG Shaoxian SHI Haibin
Department of Interventional Radiology, First Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu Province 210029, China
关键词:
是独立保护因素而女性、最大肿瘤直径≥5 cm为独立危险因素。结论 采用ESG栓塞治疗合并中重度APS的HCC患者安全、有效治疗有应答、APS改善患者预后较好而女性、最大肿瘤直径≥5 cm为患者预后危险因素。 【关键词】 无水乙醇明胶海绵混合物 栓塞治疗性 肝细胞癌 肝动脉门静脉分流 预后因素
文献标志码:
A
摘要:
【摘要】 目的 探讨采用无水乙醇明胶海绵混合物(ESG)联合化疗药物和/或碘化油,对合并中重度肝动脉门静脉分流(APS)的肝癌(HCC)患者行末梢性化疗栓塞的安全性和有效性。方法 回顾性分析2008年6月至2015年12月使用ESG栓塞治疗106例HCC合并中重度APS患者的临床资料,对于手术前后APS改善情况、手术相关并发症、肿瘤反应、生存期和预后因素等进行统计学分析。结果 106例HCC合并中重度APS的患者中位生存期为278 d,6、12、18个月累积生存率分别为70.8%、36.1%、16.0%。单因素分析结果显示:性别、总胆红素水平、最大肿瘤直径、既往治疗、治疗有无应答以及APS改善与患者预后相关。多因素分析结果显示:治疗有应答、APS改善

参考文献/References:

[1] 刘 圣, 施海彬, 杨正强, 等. α-氰基丙烯酸正丁酯栓塞治疗肝细胞癌并肝动脉-门静脉瘘的临床价值[J]. 中华放射学杂志, 2009, 43: 279- 283.
[2] 肖景坤, 吕维富, 周春泽, 等. 原发性肝癌伴动静脉瘘介入栓塞治疗62例回顾性分析[J]. 介入放射学杂志, 2014, 23: 683- 687.
[3] Huang MS, Lin Q, Jiang ZB, et al. Comparison of long- term effects between intra- arterially delivered ethanol and gelfoam for the treatment of severe arterioportal shunt in patients with hepatocellular carcinoma[J]. World J Gastroenterol, 2004, 10: 825- 829.
[4] Casasco AE, Houdart E, Gobin YP, et al. Embolization of spinal vascular malformations[J]. Neuroimag Clin N Am, 1992, 2: 337- 358.
[5] 中华人民共和国卫生部. 原发性肝癌诊疗规范(2011年版)[J]. 临床肝胆病杂志, 2011, 11: 1141- 1159.
[6] Shi HB, Yang ZQ, Liu S, et al. Transarterial embolization with cyanoacrylate for severe arterioportal shunt complicated by hepatocellular carcinoma[J]. Cardiovasc Intervent Radiol, 2013, 36: 412- 421.
[7] Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma[J]. Semin Liver Dis, 2010, 30: 52- 60.
[8] Guzinski M, Kurcz J, Tupikowski K, et al. The role of transarterial embolization in the treatment of renal tumors[J]. Adv Clin Exp Med, 2014, 24: 837- 843.
[9] Hyun D, Do YS, Park KB, et al. Ethanol embolotherapy of foot arteriovenous malformations[J]. J Vasc Surg, 2013, 58: 1619- 1626.
[10] 路延平, 秦好朴, 张孟增. 多种材料联合栓塞治疗食管胃底静脉曲张临床疗效分析[J]. 介入放射学杂志, 2011, 20: 566- 568.
[11] Furuse J, 1wasaki M, Yoshino M, et al. Hepatocellular carcinoma with portal vein tumor thrombus: embolization of arterioportal shunts[J]. Radiology, 1997, 204: 787- 790.
[12] Izaki K, Sugimoto K, Sugimura K, et al. Transcatheterarterial embolization for advanced tumor thrombus with marked arterioportal or arteriovenous shunt complicating hepatocellular carcinoma[J]. Radiat Med, 2004, 22: 155- 162.
[13] 刘秋松, 梅雀林, 李彦豪, 等. 化疗栓塞治疗肝癌合并肝动-静脉分流的预后因素分析[J]. 介入放射学杂志, 2015, 24: 1056- 1061.
[14] Terzi E, Piscaglia F, Forlani L, et al. TACE performed in patients with a single nodule of hepatocellular carcinoma[J]. BMC Cancer, 2014, 14: 601.
[15] Hwang S, Lee YJ, Kim KH, et al. The impact of tumor size on long- term survival outcomes after resection of solitary hepato- cellular carcinoma: single- institution experience with 2558 patients[J]. J Gastrointest Surg, 2015, 19: 1281.
[16] 沈新颖, 单 鸿. 肝癌合并肝动脉-门静脉分流影响门静脉血流动力学的定量研究[J]. 介入放射学杂志, 2005, 14: 21- 23.

备注/Memo

备注/Memo:
(收稿日期:2016-10-24)
(本文编辑:俞瑞纲)
更新日期/Last Update: 2017-09-12